GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » MariMed Inc (XCNQ:MRMD) » Definitions » Cyclically Adjusted PB Ratio

MariMed (XCNQ:MRMD) Cyclically Adjusted PB Ratio : 2.62 (As of May. 17, 2024)


View and export this data going back to 2022. Start your Free Trial

What is MariMed Cyclically Adjusted PB Ratio?

As of today (2024-05-17), MariMed's current share price is C$0.34. MariMed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 was C$0.13. MariMed's Cyclically Adjusted PB Ratio for today is 2.62.

The historical rank and industry rank for MariMed's Cyclically Adjusted PB Ratio or its related term are showing as below:

XCNQ:MRMD' s Cyclically Adjusted PB Ratio Range Over the Past 10 Years
Min: 2.54   Med: 7.75   Max: 25.25
Current: 2.67

During the past years, MariMed's highest Cyclically Adjusted PB Ratio was 25.25. The lowest was 2.54. And the median was 7.75.

XCNQ:MRMD's Cyclically Adjusted PB Ratio is ranked worse than
61.55% of 671 companies
in the Drug Manufacturers industry
Industry Median: 1.88 vs XCNQ:MRMD: 2.67

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

MariMed's adjusted book value per share data for the three months ended in Mar. 2024 was C$0.254. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is C$0.13 for the trailing ten years ended in Mar. 2024.

Shiller PE for Stocks: The True Measure of Stock Valuation


MariMed Cyclically Adjusted PB Ratio Historical Data

The historical data trend for MariMed's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MariMed Cyclically Adjusted PB Ratio Chart

MariMed Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 19.98 5.65 3.07

MariMed Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 5.64 5.34 5.19 3.07 2.77

Competitive Comparison of MariMed's Cyclically Adjusted PB Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, MariMed's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MariMed's Cyclically Adjusted PB Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, MariMed's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where MariMed's Cyclically Adjusted PB Ratio falls into.



MariMed Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

MariMed's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.34/0.13
=2.62

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

MariMed's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2024 is calculated as:

For example, MariMed's adjusted Book Value per Share data for the three months ended in Mar. 2024 was:

Adj_Book=Book Value per Share/CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.254/131.7762*131.7762
=0.254

Current CPI (Mar. 2024) = 131.7762.

MariMed Quarterly Data

Book Value per Share CPI Adj_Book
201406 -0.041 100.560 -0.054
201409 0.063 100.428 0.083
201412 -0.061 99.070 -0.081
201503 -0.060 99.621 -0.079
201506 -0.070 100.684 -0.092
201509 -0.056 100.392 -0.074
201512 -0.085 99.792 -0.112
201603 -0.071 100.470 -0.093
201606 -0.037 101.688 -0.048
201609 -0.037 101.861 -0.048
201612 -0.023 101.863 -0.030
201703 0.004 102.862 0.005
201706 0.038 103.349 0.048
201709 0.054 104.136 0.068
201712 0.078 104.011 0.099
201803 0.076 105.290 0.095
201806 0.147 106.317 0.182
201809 0.235 106.507 0.291
201812 0.395 105.998 0.491
201903 0.414 107.251 0.509
201906 0.505 108.070 0.616
201909 0.497 108.329 0.605
201912 0.040 108.420 0.049
202003 -0.047 108.902 -0.057
202006 -0.019 108.767 -0.023
202009 0.003 109.815 0.004
202012 0.035 109.897 0.042
202103 0.060 111.754 0.071
202106 0.095 114.631 0.109
202109 0.141 115.734 0.161
202112 0.145 117.630 0.162
202203 0.171 121.301 0.186
202206 0.185 125.017 0.195
202209 0.210 125.227 0.221
202212 0.234 125.222 0.246
202303 0.263 127.348 0.272
202306 0.295 128.729 0.302
202309 0.293 129.860 0.297
202312 0.256 129.419 0.261
202403 0.254 131.776 0.254

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


MariMed  (XCNQ:MRMD) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


MariMed Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of MariMed's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


MariMed (XCNQ:MRMD) Business Description

Traded in Other Exchanges
Address
10 Oceana Way, Floor 2, Norwood, MA, USA, 02062
MariMed Inc is a multi-state operator in the United States cannabis industry. It develops, operates, manages, and optimizes regulatory-compliant facilities for the cultivation, production, and dispensing of medical and adult-use cannabis. MariMed also licenses its proprietary brands of cannabis products along with other top brands in domestic markets Sources of revenue are comprised of Product sales (retail and wholesale), Real estate rental income, Supply procurement, Management fees, and Licensing fees.
Executives
Jon R. Levine Senior Officer
Timothy Shaw Senior Officer